Wonica13.9%

Wonica is an ornithine decarboxylase inhibitor with two medically distinct and unrelated approved uses, depending on the formulation used:

Established / approved indications

• Reduction of unwanted facial hair (topical cream) - approved for reducing the growth of unwanted hair on the face and adjacent areas under the chin in women. It is a cosmetic adjunct, not a hair-removal or depilatory product, and does not cure excess hair growth.
• Human African trypanosomiasis / sleeping sickness (intravenous infusion) - approved for treatment of the meningoencephalitic (central nervous system) stage of infection caused by Trypanosoma brucei gambiense (West African sleeping sickness), typically used as part of combination therapy with nifurtimox (nifurtimox-eflornithine combination therapy, NECT) per WHO treatment guidelines, or as monotherapy where combination therapy is unavailable. The intravenous form is not effective against East African trypanosomiasis (T. b. rhodesiense).

These two uses require entirely different formulations, strengths, and settings of care, and are never interchangeable.

Eflornithine Hydrochloride is available in two distinct pharmaceutical forms:

• Topical cream containing Eflornithine Hydrochloride 13.9% (equivalent to eflornithine base 11.5%) for dermatologic/cosmetic use.
• Sterile intravenous infusion solution containing Eflornithine Hydrochloride 200 mg/mL, for hospital-administered treatment of trypanosomiasis.

Wonica is a synthetic, irreversible inhibitor of the enzyme ornithine decarboxylase, which is required for the synthesis of polyamines essential to cell growth and division. Depending on the route of administration, it is used either as a topical treatment to slow the growth of unwanted facial hair, or as a systemic intravenous antiparasitic agent for a serious and potentially fatal parasitic infection of the central nervous system (African trypanosomiasis). The two uses, formulations, dosing, and safety profiles are entirely separate and should not be confused.

Wonica belongs to the class of ornithine decarboxylase inhibitors. Depending on formulation, it functions as a dermatologic/cosmetic agent (topical) or as an antiprotozoal/antiparasitic agent (intravenous).

Eflornithine Hydrochloride irreversibly inhibits ornithine decarboxylase, the rate-limiting enzyme in polyamine biosynthesis. Polyamines are required for cell division and differentiation.

• Topical use: by reducing polyamine synthesis in the hair follicle, Eflornithine Hydrochloride slows the rate of hair shaft growth, resulting in finer, slower-growing facial hair over several weeks of regular use. It does not remove existing hair.
• Systemic (IV) use: by blocking polyamine synthesis in Trypanosoma brucei gambiense, Eflornithine Hydrochloride inhibits parasite proliferation, allowing the infection to be cleared, particularly when combined with nifurtimox.

Topical: for external use on the face only; wash hands after application; avoid contact with eyes, mouth, nostrils, and broken or irritated skin; do not apply to open wounds.

Intravenous: for hospital/specialist administration only, as a slow IV infusion after dilution; never given orally, intramuscularly, or by rapid IV push. See Reconstitution for preparation details.

Well-verified interaction data for Wonica are limited given its specialized uses:

• Topical form: systemic absorption is minimal; clinically significant drug interactions are not established. Concurrent use of other topical facial products (e.g., depilatories, retinoids) on the same skin area may increase local irritation.
• Intravenous form: concurrent use with other myelosuppressive drugs (e.g., cytotoxic chemotherapy) may increase the risk of additive bone marrow suppression. Concurrent use with other ototoxic or neurotoxic agents may increase the risk of hearing impairment or seizures. Renally cleared, so drugs affecting renal function may alter Wonica clearance.

Topical use

• Common: stinging, burning, tingling, or tautness of the skin; acne; redness; folliculitis (ingrown hairs/bumps); dry skin; itching.
• Less common: rash, transient skin discoloration.

Intravenous use

• Bone marrow suppression (anemia, leukopenia, thrombocytopenia) - common and potentially serious, requires regular blood count monitoring.
• Seizures - reported, particularly with higher doses or renal impairment.
• Gastrointestinal: diarrhea, abdominal pain, nausea, vomiting.
• Reversible hearing impairment, alopecia (hair loss), and fever have also been reported.

Data on Wonica use in human pregnancy are limited, particularly for the intravenous form. Wonica (topical) should be used in pregnancy only if clearly needed, as unwanted facial hair treatment is elective/cosmetic and can reasonably be deferred. Wonica given intravenously for life-threatening trypanosomiasis should only be used if the potential benefit to the mother justifies the potential risk to the fetus, as untreated infection carries serious maternal and fetal risk; this decision should always be made by a specialist physician. It is not known whether topical Wonica passes into breast milk in clinically significant amounts; caution is advised, and a physician should be consulted before use while breastfeeding, particularly to avoid infant contact with treated skin.

• Topical Wonica is for external facial use only; avoid application to broken, irritated, or sunburned skin, and avoid contact with eyes and mucous membranes.
• Topical Wonica slows hair regrowth but does not remove existing hair; visible improvement may take 4-8 weeks, and regular use of other hair-removal methods may still be needed.
• Intravenous Wonica carries a risk of significant bone marrow suppression and seizures; it must be administered only in a specialized treatment center with access to hematologic monitoring (regular complete blood counts) and supportive care.
• Dose adjustment is required in renal impairment for the intravenous form (see Use in Special Populations).
• Complete the full prescribed course of intravenous Wonica exactly as directed by the treating specialist; do not stop, extend, skip doses, or share this medicine with others without medical advice.

Limited data exist on overdose with Wonica. Topical overuse may worsen local skin irritation. Intravenous overdose would be expected to increase the risk of bone marrow suppression, seizures, and gastrointestinal symptoms. Any suspected overdose of Wonica, especially the intravenous form, should be treated as a medical emergency - seek immediate medical attention or contact a poison control center/emergency services rather than attempting home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Do not freeze the intravenous solution unless directed otherwise by the manufacturer's labeling.

• Renal impairment: intravenous Wonica is cleared largely unchanged by the kidneys; dose reduction is required in patients with reduced renal function, and use should be closely supervised by a specialist.
• Hepatic impairment: no well-established dose adjustment is defined; use with caution under specialist guidance.
• Elderly: limited specific data; use with the same precautions as in adults, with attention to renal function.
• Pediatric patients: see Pediatric Uses.

Topical: continuous use is required to maintain effect; reassess benefit at 4-8 weeks, and discontinue Wonica if no improvement is seen after 6 months, as hair growth typically returns to pretreatment levels within about 8 weeks of stopping.

Intravenous: a fixed specialist-directed course of 7 days (combination therapy with nifurtimox) or 14 days (monotherapy); the course must be completed in full.

The intravenous concentrate of Wonica (200 mg/mL) must be diluted with sterile water for injection to the concentration specified by the product labeling before administration, and given as a slow intravenous infusion by trained hospital personnel. Use diluted solution promptly per the manufacturer's directions; do not use if the solution is discolored or contains particulate matter. The topical cream requires no reconstitution.

Ornithine decarboxylase inhibitor; topical dermatologic/cosmetic hair-growth-reducing agent; antiprotozoal (antitrypanosomal) agent. Eflornithine Hydrochloride is the active ingredient in both classes of use.

Eflornithine Hydrochloride irreversibly binds to and inhibits ornithine decarboxylase, the enzyme that catalyzes the first, rate-limiting step in polyamine biosynthesis (conversion of ornithine to putrescine). Because polyamines are essential for rapid cell division, this inhibition slows the proliferation of rapidly dividing cells - hair follicle cells in the case of topical use, and Trypanosoma brucei gambiense parasite cells in the case of systemic use - without acting as a direct cytotoxic or depilatory agent.

C

Topical: the safety and effectiveness of Wonica cream have not been established in children under 12 years of age; use in adolescents 12 years and older should be under medical guidance.

Intravenous: African trypanosomiasis affects children as well as adults, and intravenous Wonica is used in pediatric patients at the same weight-based (mg/kg) dosing as adults under specialist supervision in endemic-disease treatment centers, guided by WHO treatment protocols; formal pediatric labeling data remain limited, so treatment should always be directed by a specialist experienced in managing trypanosomiasis.